

Attorney Docket No.: 6004.200-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#6
S.G.J
1/8/00

Application of: Belghuith et al.

Application No.: 09/383,318

Group Art Unit: 1646

Filed: August 26, 1999

Examiner: TBA

For: "Polypeptides Having Glucose Isomerase Activity And Nucleic Acids Encoding Same"

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Bejar et al., Biotechnology Letters, Vol. 16, No. 12, pp. 1259-1264 (Dec. 1994)
2. Meaden et al., Gene, Vol. 141, pp. 97-101, (1994)
3. Wuxiang et al., Biotechnology Letters, Vol. 15, No. 11, pp. 1101-1106 (Nov. 1993)

4. Brown et al., Biotechnology and Bioengineering, Vol. 41, pp. 878-886 (1993)
5. Dekker et al., Appl. Microbiol. Biotechnol., Vol. 36, pp. 727-732 (1992)
6. Belghith et al., Biotechnology Letters, Vol. 20, No. 6, pp. 553-556 (June 1998)
7. Wong et al., Journal of Bacteriology, Vol. 173, No. 21, pp. 6849-6858 (Nov. 1991)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Respectfully submitted,

Date: December 15, 1999

Carol E. Rozek
Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123